Corcept Therapeutics Förvaltning
Förvaltning kriterier kontrolleras 2/4
Corcept Therapeutics VD är Joseph Belanoff, utsedd i Jan 1999, har en mandatperiod på 27.42 år. totala årliga ersättningen är $ 15.30M, bestående av 7.7% lön 92.3% bonusar, inklusive företagsaktier och optioner. äger direkt 2.67% av företagets aktier, värda $ 210.13M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 5.6 år respektive 24.7 år.
Viktig information
Joseph Belanoff
Verkställande direktör
US$15.3m
Total ersättning
| VD-lön i procent | 7.73% |
| Anställning som VD | 27.4yrs |
| Ägande av VD | 2.7% |
| Ledningens genomsnittliga anställningstid | 5.6yrs |
| Styrelsens genomsnittliga mandatperiod | 24.7yrs |
Senaste uppdateringar av ledningen
Recent updates
Uppdatering av berättelse • Jun 06
CORT: Ovarian Cancer Data And Cushing’s Resubmission Will Drive Future Upside
Corcept Therapeutics' updated analyst price target has increased to $88.00 from $73.40, reflecting analysts' focus on recent price target revisions associated with the relacorilant NDA resubmission and the launch of Lifyorli in ovarian cancer. Analyst Commentary Recent Street research around Corcept Therapeutics centers on two main themes, the relacorilant regulatory path and the commercial opportunity for Lifyorli in ovarian cancer, with both feeding directly into updated valuation work.Uppdatering av berättelse • May 11
CORT: New Ovarian Cancer Therapy Approval Will Support Future Upside
Analysts have raised Corcept Therapeutics' implied fair value target to $73.40 from $67.40. This reflects updated assumptions that indicate higher revenue growth and profit margins, slightly offset by a higher discount rate and a lower future P/E multiple following recent mixed price target revisions and a rating upgrade on the stock.Seeking Alpha • May 04
Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement
Summary Corcept Therapeutics Incorporated remains a Strong Buy following early FDA approval of Lyforli [relacorilant] plus nab-paclitaxel for platinum-resistant ovarian cancer [PROC]. The company expects further upside from European approval, additional oncology indications, and a triple-combo study with Avastin, with key data and decisions anticipated by year-end. Phase 2 data for dazucorilant in ALS showed significant 1- and 2-year survival benefits, supporting a planned phase 3 study targeting overall survival as a primary endpoint. CORT 2026 revenue guidance was raised to $950–$1,050 million, driven by strong Lyforli uptake and robust Korlym sales, though risks include EU approval uncertainty and potential pricing pressures. Read the full article on Seeking AlphaUppdatering av berättelse • Apr 25
CORT: Ovarian Cancer Approval Will Support Future Upside Despite Patent Setback
Analysts have adjusted their price targets on Corcept Therapeutics, with changes such as H.C. Wainwright moving its target to $67, alongside offsetting increases from firms like Canaccord. These moves reflect updated views on patent risk, generic competition and the long term earnings profile implied by largely unchanged fair value, revenue growth, profit margin and future P/E assumptions.Uppdatering av berättelse • Apr 11
CORT: Ovarian Cancer Approval Will Support Future Upside Despite Generic Headwinds
Corcept Therapeutics' updated analyst price target has been reset to $67, with analysts citing a tempered revenue growth outlook, slightly stronger expected profit margins, and an unchanged fair value and future P/E assumption. Analyst Commentary Recent Street research on Corcept Therapeutics reflects a mixed but engaged view, with several firms recalibrating price targets and ratings after legal and regulatory updates.Uppdatering av berättelse • Mar 27
CORT: Ovarian Cancer Approval Will Drive Future Upside Despite Generic Risk
Corcept Therapeutics' updated analyst price target has moved to $67.40 from $65.40. Analysts cite refined fair value assumptions and a slightly higher future P/E multiple as they reassess the stock following mixed target changes across recent research coverage.Uppdatering av berättelse • Mar 10
CORT: Future Generic Ruling And Oncology Data Will Drive Upside
Analysts have reduced their price target on Corcept Therapeutics to $67 from $105, reflecting lower fair value assumptions and revised expectations for revenue growth and profit margins after the court ruling that allows Teva's generic Korlym to participate in the Cushing's syndrome market. Analyst Commentary Recent research on Corcept Therapeutics clusters around the patent ruling on Teva's generic Korlym and its implications for the Cushing's syndrome market.Uppdatering av berättelse • Feb 24
CORT: Future Court Ruling And Oncology Data Will Drive Long Term Upside
Analysts have reduced their fair value estimate for Corcept Therapeutics from $94.20 to $76.40 and the implied future P/E from 18.66x to 16.90x, reflecting a lower price target from $105 to $67 following the court decision allowing Teva's generic Korlym to compete, along with a more cautious view on revenue growth and profit margins. Analyst Commentary Recent research updates on Corcept Therapeutics focus heavily on the legal outcome around Teva's generic Korlym and what that could mean for valuation, growth expectations, and execution risk.Uppdatering av berättelse • Feb 09
CORT: Future Regulatory And Oncology Outcomes Will Drive Long Term Upside
Analysts have raised their price target on Corcept Therapeutics by about $1, citing updated models that reflect steady assumptions for fair value, revenue growth, profit margins and future P/E. Recent research maintains the overall investment thesis despite regulatory developments.Uppdatering av berättelse • Jan 26
CORT: Future Endocrine And Oncology Decisions Will Drive Long Term Upside
Narrative Update: Corcept Therapeutics Analysts have lifted their fair value estimate for Corcept Therapeutics to $94.20 from $91.00, citing updated assumptions around higher revenue growth, stronger profit margins, and a slightly lower future P/E multiple in their latest models. Analyst Commentary Recent research on Corcept Therapeutics has focused on how its Cushing's syndrome franchise could support long term growth, while also highlighting uncertainties around future positioning and execution.Uppdatering av berättelse • Jan 10
CORT: Upcoming Endocrine And Oncology Decisions Will Shape Long Term Upside
Analysts have reset their price target framework for Corcept Therapeutics from about $127 to roughly $91, reflecting updated assumptions around revenue growth, profit margins, and a higher future P/E multiple, informed in part by recent coverage that compares relacorilant and Korlym with existing Cushing's syndrome treatments. Analyst Commentary Street research around Corcept Therapeutics is limited in the recent set of notes, but one new initiation helps frame how some investors might think about both the clinical and valuation setup for the stock.Analysartikel • Jan 01
The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56%
Corcept Therapeutics Incorporated ( NASDAQ:CORT ) shareholders that were waiting for something to happen have been...Uppdatering av berättelse • Dec 17
CORT: Upcoming Ovarian Cancer Decisions May Drive Upside Despite Pharmacy Transition Risks
Analysts have modestly trimmed their price target on Corcept Therapeutics to $127.20 from $134.50, reflecting a slightly higher discount rate. They also point to stronger long term revenue growth, expanding profit margins and a lower future P E multiple supported by continued confidence in the commercial potential of Korlym and relacorilant.Analysartikel • Oct 07
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable
The Corcept Therapeutics Incorporated ( NASDAQ:CORT ) share price has done very well over the last month, posting an...Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$47m |
| Dec 31 2025 | US$15m | US$1m | US$98m |
| Sep 30 2025 | n/a | n/a | US$105m |
| Jun 30 2025 | n/a | n/a | US$132m |
| Mar 31 2025 | n/a | n/a | US$133m |
| Dec 31 2024 | US$10m | US$1m | US$140m |
| Sep 30 2024 | n/a | n/a | US$140m |
| Jun 30 2024 | n/a | n/a | US$125m |
| Mar 31 2024 | n/a | n/a | US$117m |
| Dec 31 2023 | US$9m | US$1m | US$105m |
| Sep 30 2023 | n/a | n/a | US$91m |
| Jun 30 2023 | n/a | n/a | US$94m |
| Mar 31 2023 | n/a | n/a | US$94m |
| Dec 31 2022 | US$7m | US$896k | US$101m |
| Sep 30 2022 | n/a | n/a | US$117m |
| Jun 30 2022 | n/a | n/a | US$113m |
| Mar 31 2022 | n/a | n/a | US$112m |
| Dec 31 2021 | US$11m | US$844k | US$113m |
| Sep 30 2021 | n/a | n/a | US$106m |
| Jun 30 2021 | n/a | n/a | US$98m |
| Mar 31 2021 | n/a | n/a | US$99m |
| Dec 31 2020 | US$6m | US$770k | US$106m |
| Sep 30 2020 | n/a | n/a | US$109m |
| Jun 30 2020 | n/a | n/a | US$114m |
| Mar 31 2020 | n/a | n/a | US$106m |
| Dec 31 2019 | US$5m | US$708k | US$94m |
Ersättning vs marknad: Joseph s total kompensation ($USD 15.30M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 8.38M ).
Ersättning vs inkomst: Ersättningen för Joseph har ökat med mer än 20 % medan företagets intäkter har minskat med mer än 20 % det senaste året.
VD OCH KONCERNCHEF
Joseph Belanoff (69 yo)
27.4yrs
Anställning
US$15,303,551
Kompensation
Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Co-Founder | 27.4yrs | US$15.30m | 2.67% $ 210.1m | |
| CFO & Treasurer | 5.3yrs | US$6.14m | 0.015% $ 1.2m | |
| President of Endocrinology | 10.2yrs | US$6.21m | 0.11% $ 8.8m | |
| Chief Development Officer | 4.8yrs | US$6.34m | 0.0037% $ 292.1k | |
| Chief Business Officer & Secretary | 12.4yrs | US$6.38m | 0.094% $ 7.4m | |
| Chief Technology & Accounting Officer | 5.9yrs | inga uppgifter | 0.0066% $ 515.6k | |
| Chief Scientific Officer | 5.9yrs | US$3.11m | 0.24% $ 18.7m | |
| Chief Human Resources & Communications Officer | 4.9yrs | inga uppgifter | inga uppgifter | |
| President of Emerging Markets | 2.6yrs | inga uppgifter | inga uppgifter | |
| President of Oncology | 2.4yrs | inga uppgifter | inga uppgifter |
5.6yrs
Genomsnittlig anställningstid
55.5yo
Genomsnittlig ålder
Erfaren ledning: CORT s ledningsgrupp är erfaren och erfaren ( 5.6 års genomsnittlig anställning).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Co-Founder | 27.4yrs | US$15.30m | 2.67% $ 210.1m | |
| Independent Director | 27.4yrs | US$768.00k | 5.17% $ 407.0m | |
| Independent Director | 21.9yrs | US$784.50k | 1.2% $ 94.1m | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Independent Chairman | 27.4yrs | US$1.29m | 1.4% $ 110.3m | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Independent Director | 6.3yrs | US$787.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Independent Director | 6.8yrs | US$764.99k | 0% $ 0 |
24.7yrs
Genomsnittlig anställningstid
70.5yo
Genomsnittlig ålder
Erfaren styrelse: CORT s styrelse är rutinerade och erfaren ( 24.7 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/09 10:32 |
| Aktiekurs vid dagens slut | 2026/06/09 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Corcept Therapeutics Incorporated bevakas av 18 analytiker. 5 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Debjit Chattopadhyay | Brean Capital Historical (Janney Montgomery) |
| David Buck | B. Riley Securities, Inc. |